Phase II trial of Remitogen™ (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma

被引：27

作者：

Brown, KS

Levitt, DJ

Shannon, M

Link, BK

机构：

[1] Univ Iowa, Dept Internal Med, Div Hematol Oncol & Blood & Marrow Transplant, Iowa City, IA 52242 USA

[2] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA

[3] Prot Design Labs, Fremont, CA USA

来源：

CLINICAL LYMPHOMA | 2001年 / 2卷 / 03期

关键词：

D O I：

10.3816/CLM.2001.n.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：188 / 190

页数：3

共 10 条

[1]

ALTOMONTE M, 1993, J IMMUNOL, V151, P5115

[2] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[3]

Coiffier B, 1998, BLOOD, V92, P1927

[4]

Coiffier B, 2000, BLOOD, V96, p223A

[5]

GINGRICH RD, 1990, BLOOD, V75, P2375

[6]

Green JM, 2000, BLOOD, V96, p133A

[7] GROWTH-INHIBITION OF EPSTEIN-BARR VIRUS-TRANSFORMED B-CELLS BY ANTI-HLA-DR ANTIBODY L243 - POSSIBLE RELATIONSHIP TO L243-INDUCED DOWN-REGULATION OF CD23 ANTIGEN EXPRESSION [J].

KABELITZ, D ;

JANSSEN, O .

CELLULAR IMMUNOLOGY, 1989, 120 (01) :21-30

[8] Humanization and characterization of the anti-HLA-DR antibody 1D10 [J].

Kostelny, SA ;

Link, BK ;

Tso, JY ;

Vasquez, M ;

Jorgensen, BH ;

Wang, H ;

Hall, WC ;

Weiner, GJ .

INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (04) :556-565

[9]

Link BK, 2000, P AM SOC CLIN ONCOL, V19, p24a

[10]

Maloney DG, 1997, BLOOD, V90, P2188

← 1 →